TISIDB

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus membrane Single-pass type II membrane protein
Domain	PF00777 Glycosyltransferase family 29 (sialyltransferase)
Function	Catalyzes the formation of ganglioside GM3 (alpha-N-acetylneuraminyl-2,3-beta-D-galactosyl-1, 4-beta-D-glucosylceramide).

> Gene Ontology [ TOP ]
Biological Process	GO:0001573 ganglioside metabolic process GO:0001574 ganglioside biosynthetic process GO:0006486 protein glycosylation GO:0006487 protein N-linked glycosylation GO:0006643 membrane lipid metabolic process GO:0006664 glycolipid metabolic process GO:0006665 sphingolipid metabolic process GO:0006672 ceramide metabolic process GO:0006687 glycosphingolipid metabolic process GO:0006688 glycosphingolipid biosynthetic process GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0009247 glycolipid biosynthetic process GO:0009311 oligosaccharide metabolic process GO:0018196 peptidyl-asparagine modification GO:0018279 protein N-linked glycosylation via asparagine GO:0030148 sphingolipid biosynthetic process GO:0043413 macromolecule glycosylation GO:0044723 single-organism carbohydrate metabolic process GO:0046467 membrane lipid biosynthetic process GO:0046513 ceramide biosynthetic process GO:0070085 glycosylation GO:0097503 sialylation GO:1903509 liposaccharide metabolic process
Molecular Function	GO:0003836 beta-galactoside (CMP) alpha-2,3-sialyltransferase activity GO:0004513 neolactotetraosylceramide alpha-2,3-sialyltransferase activity GO:0008373 sialyltransferase activity GO:0016757 transferase activity, transferring glycosyl groups GO:0047291 lactosylceramide alpha-2,3-sialyltransferase activity
Cellular Component	GO:0030173 integral component of Golgi membrane GO:0031228 intrinsic component of Golgi membrane GO:0031300 intrinsic component of organelle membrane GO:0031301 integral component of organelle membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00604 Glycosphingolipid biosynthesis - ganglio series hsa01100 Metabolic pathways
Reactome	R-HSA-446203: Asparagine N-linked glycosylation R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification R-HSA-4085001: Sialic acid metabolism R-HSA-446219: Synthesis of substrates in N-glycan biosythesis

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ST3GAL5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ST3GAL5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ST3GAL5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	1.09	0.04
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.846	0.462
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.544	0.762
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.299	0.494
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.086	0.965
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.559	0.801
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.438	0.285
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.256	0.887
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.667	0.742
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.265	0.854
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.499	0.802
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.047	0.813

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ST3GAL5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ST3GAL5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ST3GAL5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ST3GAL5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ST3GAL5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ST3GAL5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ST3GAL5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ST3GAL5
Name	ST3 beta-galactoside alpha-2,3-sialyltransferase 5
Aliases	ST3GalV; SIATGM3S; SIAT9; sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 s ......
Chromosomal Location	2p11.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ST3GAL5 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ST3GAL5.

ID	Name	Drug Type	Targets	#Targets
DB05867	99mTc-14 F7 Mab	Biotech	ST3GAL5	1

Browse ST3GAL5